What the trial was testing
The CAPTAIN enrolled 2,436 patients with asthma. The study was sponsored by GlaxoSmithKline and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
The triple-drug inhaler improved lung capacity by 110 mL more than the standard two-drug version.
The Lancet. Respiratory medicine · 2021 · NCT02924688
These findings — that triple-drug inhaler boosted breathing volume more than standard two-drug treatment — were published in the The Lancet. Respiratory medicine and represent the headline result of the study.
Researchers tracked outcomes across 2,436 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with asthma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This triple-combination inhaler is FDA-approved and available now for asthma patients who aren't well-controlled on a steroid plus long-acting bronchodilator. It improved breathing capacity significantly, though it didn't dramatically cut asthma attacks in this study. If your current asthma treatment isn't working well enough, ask your doctor whether adding a third medicine to your inhaler might help.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open asthma trials
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 subjects are expected to be enrolled, with subjects randomized in a 1:1 ratio to receive either TQC2731 (420 mg Q4W) or placebo (Q4W) via subcutaneous (SC) administration.
Is There a Benefit From Addition of Physical Exercise to Diet Restriction/Limitation in PCOS Women With Asthma?
Women with polysyctic ovarian syndrome (PCOS) usually develop many complications including asthma. Nowdays, diet restriction combimed with phsyical exercises may improve both problems